Home › Anterior Cruciate Ligament Injuries › NCT04572256

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

Who can join

Ages 25 to 50 · All sexes

Inclusion Criteria:

1. Undergoing primary ACL reconstruction
2. Age between 25-50
3. Concomitant meniscus injury

Exclusion Criteria:

1. Undergoing revision procedures
2. Multiple ligament injuries requiring multiple ligament reconstruction/repair
3. Depressive symptoms and/or those who endorse suicidal ideation at the time of enrollment (PHQ-9 score \>= 15)
4. Found to not have a meniscus tear at the time of surgery

About the study

This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.

What is being tested

• Montelukast (drug)
• Placebo (drug)

Sponsor: Austin V Stone · Participants: 30 · Started: Feb 1, 2021

Contact the study team

• Austin Stone, MD, PhD · Phone: 859.218.3065

Official record on ClinicalTrials.gov — NCT04572256

Locations in the U.S.

Conditions

• Anterior Cruciate Ligament Injuries
• Osteoarthritis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.